1Stefan L, Kristian W, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis, Lancet, 2003; 361 : 1581-1589. 被引量：1
2Soares BC, O, Fenton M, Chue P. Sulpiride for schizophrenia. The Cochrane Collaboration, 2005; (4). 被引量：1
3Awad G, et al. New antipsychotics, compliance, quality of life, and subjective tolerability-are patients better off?. Can J Psychiatry, 2004; 49: 297-302. 被引量：1
4Iasser R, Bossie C, et al. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder, Int J Geriatr Psychiatry, 2004; 19: 898-905. 被引量：1
5Ko SY, Chen PS, Yang YK, et al. Correlation between scores on Continuous Performance Test and plasma concentration for schizophrenic patients on risperidone. Psychiatry and Clinical Neuroscience, 2004; 58: 168-172. 被引量：1
6Lindenmayer JP, Volavka J, Lieberman J, et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J Clin Psychopharmacol. 2001; 21: 448. 被引量：1
7Revicki DA. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr Opin Invesaig Drugs, 2001 ; 2 (1) : 110-117. 被引量：1
8Tandon R. Quetiapine has a direct effect on the negative symptoms of schizophrenia. Hum Psychopharmacol Clin Exp. 2004;19: 559-563. 被引量：1
9Comblatt B, Kern RS, Carson WH, et al. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. Int J Neuropsychopharmacol. 2002; 1 : 185-186. 被引量：1
10Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stablized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry, 2003:64 (9): 1048-1056. 被引量：1
